Evidence map›Paper›PMID 26230546›Full record

ArticlePloS one2015

Towards Personalized Cardiology: Multi-Scale Modeling of the Failing Heart.

Elham Kayvanpour, Tommaso Mansi, Farbod Sedaghat-Hamedani, Ali Amr, Dominik Neumann, Bogdan Georgescu, Philipp Seegerer, Ali Kamen, Jan Haas, Karen S Frese and 10 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Syncytin-1, syncytin-2 and suppressyn in human health and disease.Journal of molecular medicine (Berlin, Germany) · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Elham KayvanpourDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany.
Tommaso MansiSiemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America.
Farbod Sedaghat-HamedaniDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany.
Ali AmrDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany.
Dominik NeumannSiemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America.
Bogdan GeorgescuSiemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America.
Philipp SeegererSiemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America.
Ali KamenSiemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America.
Jan HaasDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany.
Karen S FreseDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany.
Maria IrawatiDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany.
Emil WirszSiemens AG, Corporate Technology, Erlangen, Germany.
Vanessa KingSiemens Corporation, Corporate Technology, Sensor Technologies, Princeton, New Jersey, United States of America.
Sebastian BussDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany.
Derliz MerelesDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany.
Edgar ZitronDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany.
Andreas KellerBiomarker Discovery Center Heidelberg, Heidelberg, Germany; Department of Human Genetics, Saarland University, Homburg, Germany.
Hugo A KatusDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany; Klaus Tschira Institute for Computational Cardiology, Heidelberg, Germany.
Dorin ComaniciuSiemens Corporation, Corporate Technology, Imaging and Computer Vision, Princeton, New Jersey, United States of America.
Benjamin MederDepartment of Medicine III, University of Heidelberg, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Heidelberg, Germany; Klaus Tschira Institute for Computational Cardiology, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite modern pharmacotherapy and advanced implantable cardiac devices, overall prognosis and quality of life of HF patients remain poor. This is in part due to insufficient patient stratification and lack of individualized therapy planning, resulting in less effective treatments and a significant number of non-responders. METHODS AND

resultsState-of-the-art clinical phenotyping was acquired, including magnetic resonance imaging (MRI) and biomarker assessment. An individualized, multi-scale model of heart function covering cardiac anatomy, electrophysiology, biomechanics and hemodynamics was estimated using a robust framework. The model was computed on n=46 HF patients, showing for the first time that advanced multi-scale models can be fitted consistently on large cohorts. Novel multi-scale parameters derived from the model of all cases were analyzed and compared against clinical parameters, cardiac imaging, lab tests and survival scores to evaluate the explicative power of the model and its potential for better patient stratification. Model validation was pursued by comparing clinical parameters that were not used in the fitting process against model parameters.

conclusionThis paper illustrates how advanced multi-scale models can complement cardiovascular imaging and how they could be applied in patient care. Based on obtained results, it becomes conceivable that, after thorough validation, such heart failure models could be applied for patient management and therapy planning in the future, as we illustrate in one patient of our cohort who received CRT-D implantation.

Indexed as

Precision MedicineHeart FailureHumans

Identifiers

PMID26230546
PMCPMC4521877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.